Longeveron (LGVN) EBT Growth (1y) (2021 - 2026)
Longeveron (LGVN) EBT Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
13.34% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
-51.60% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
-79.57% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-313.33% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
71.54% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Longeveron |
20.35 Bn |
20.33 Bn |
264,000.00 |
7.84% |
| Date | Value |
|---|
| Mar 31, 2026 |
7.84% |
| Dec 31, 2025 |
-26.12% |
| Sep 30, 2025 |
-57.24% |
| Jun 30, 2025 |
-54.20% |
| Mar 31, 2025 |
-26.67% |
| Dec 31, 2024 |
21.31% |
| Sep 30, 2024 |
9.92% |
| Jun 30, 2024 |
38.73% |
| Mar 31, 2024 |
13.27% |
| Dec 31, 2023 |
18.05% |
| Sep 30, 2023 |
0.50% |
| Jun 30, 2023 |
-35.32% |
| Mar 31, 2023 |
-38.95% |
| Dec 31, 2022 |
-64.59% |
| Sep 30, 2022 |
-5.73% |
| Jun 30, 2022 |
16.65% |
| Mar 31, 2022 |
1.85% |
| Dec 31, 2021 |
-190.98% |
| Sep 30, 2021 |
-409.98% |
| Jun 30, 2021 |
-313.05% |
